非器官局限性尿路上皮膀胱癌中非手术治疗与根治性膀胱切除术的生存结局及时间趋势
基于监测、流行病学和最终结果数据库(2005-2021年),分析7401例非器官局限性尿路上皮膀胱癌患者,22.2%接受双模式治疗(BMT),11.9%接受三模式治疗(TMT),65.8%接受根治性膀胱切除术(RC)加围手术期化疗(CT)。倾向性评分匹配后,BMT的5年癌症特异性死亡率(CSM)为66.2%,高于RC+CT的44.9%(多变量HR 2.12,P<.001);TMT的5年CSM为61.1%,高于RC的46.6%(多变量HR 1.63,P<.001)。BMT和TMT的使用率在研究期间无显著变化。
要点
- 非器官局限性尿路上皮膀胱癌中约三成患者接受BMT或TMT,使用率在研究期间无显著变化。
- 匹配后BMT的5年CSM为66.2%,高于RC+CT的44.9%(多变量HR 2.12,P<.001)。
- 匹配后TMT的5年CSM为61.1%,高于RC的46.6%(多变量HR 1.63,P<.001)。
核心结论
- 约十分之三的非器官局限性尿路上皮膀胱癌患者接受BMT或TMT,但此类实践均与相对于RC+CT更高的CSM相关。
- 这些观察结果应在临床决策和知情同意前进行讨论。
研究设计与样本
- 基于监测、流行病学和最终结果数据库(2005-2021年)的回顾性队列研究。
- 共纳入7401例非器官局限性(T3-4和/或N1-3)尿路上皮膀胱癌患者。
- 采用最近邻1:1倾向性评分匹配(匹配年龄、性别、分期和种族/民族)。
- 拟合单变量和多变量竞争风险回归模型,并进行T3-4,N0患者的敏感性分析。
主要发现
- 7401例患者中,1645例(22.2%)接受BMT,884例(11.9%)接受TMT,4872例(65.8%)接受RC+CT。
- 研究期间BMT和TMT的使用率无显著变化。
- 倾向性评分匹配后,BMT的5年CSM率为66.2%,RC+CT为44.9%;BMT相对于RC+CT的多变量HR为2.12(P<.001)。
- 倾向性评分匹配后,TMT的5年CSM率为61.1%,RC为46.6%;TMT相对于RC的多变量HR为1.63(P<.001)。
- 在T3-4,N0患者中发现了几乎相同的结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether bimodal therapy (BMT) or trimodal therapy (TMT) differ from radical cystectomy (RC) + perioperative chemotherapy (CT) in cancer control outcomes among patients with non-organ-confined (NOC; T3-4 and/or N1-3) urothelial carcinoma of the urinary bladder (UCUB). METHODS: Within the Surveillance, Epidemiology, and End Results database (2005-2021), rates of BMT vs TMT vs RC + CT use in NOC UCUB patients were tabulated. Nearest-neighbor 1:1 propensity score matching (PSM) for age, sex, stage, and race/ethnicity was applied. Cumulative incidence plots depicted 5-year cancer-specific (CSM) and other-cause mortality (OCM) rates. Univariable and multivariable competing risks regression (CRR) models were fitted. Sensitivity analyses focused within T3-4,N0 patients. RESULTS: Of 7401 NOC UCUB patients, 1645 (22.2%) received BMT vs 884 (11.9%) TMT vs 4872 (65.8%) RC+CT. Over the study period, BMT and TMT rates have not significantly changed. After PSM, the five-year CSM rate was 66.2% after BMT vs 44.9% after RC + CT and BMT was associated with 2.1-fold higher CSM relative to RC + CT (multivariable HR [mHR]: 2.12, P <.001). After PSM, 5-year CSM rates was 61.1% after TMT vs 46.6% after RC and TMT was associated with 1.6-fold higher CSM relative to RC (mHR: 1.63, P <.001). Virtually the same findings were found within T3-4,N0 patients. CONCLUSION: Approximately three out of ten NOC UCUB patients were treated with either BMT or TMT. However, such practice was invariably associated with higher CSM relative to RC + CT. These observations should be discussed at clinical decision-making and prior to informed consent.
引用
- Longoni M, Rodriguez Peñaranda N, Marmiroli A, et al. Survival Outcomes and Temporal Trends of Non-Surgical Management Vs Radical Cystectomy in Non-Organ-Confined Urothelial Bladder Cancer. Urology. 2025. PMID: 40057122. doi:10.1016/j.urology.2025.02.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。